QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.071415v1 311/3/1154    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Misra, S. Articles by Grider, J. R. Search for Related Content PubMed PubMed Citation Articles by Misra, S. Articles by Grider, J. R.

CELLULAR AND MOLECULAR

Coexpression of Y₁, Y₂, and Y₄ Receptors in Smooth Muscle Coupled to Distinct Signaling Pathways

Departments of Physiology and Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia

Coexpression of Y₁, Y₂, and Y₄ receptors on smooth muscle cells was determined by reverse transcription-polymerase chain reaction, and the receptors were characterized by radioligand binding, selective receptor protection, and functional analysis of signaling pathways. ¹²⁵I-peptide YY (PYY) binding was completely inhibited by neuropeptide Y (NPY) and PYY, and partially inhibited by the Y₁ agonist [Leu³¹, Pro³⁴]NPY or the Y₂ agonist NPY_13–36. In cells where Y₁ receptors were preserved by selective receptor protection, ¹²⁵I-PYY binding was selectively inhibited by the Y₁ agonist or antagonist BIBP 3226 [(R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine-amide]. Conversely, in cells where Y₂ receptors were preserved, ¹²⁵I-PYY binding was selectively inhibited by the Y₂ agonist or antagonist BIIE 0246 [(S)N²-[1-[2-[4-[(R,S)-5,11-dihydro-6(66H)-oxodibenz[b,e]azepin-11-y]-1piperazinyl]-2-oxoethyl]cyclopentyl]acetyl]-N-[2-[1,2-dihydro-35(4H)-dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl]ethyl]-argininamide]. All Y receptors activated preferentially G_i2, but only Y₂ and Y₄ receptors activated G_q. Consequently, Y₂ agonists (NPY, PYY, and NPY_13–36) and the Y₄ agonist (pancreatic polypeptide) induced concentration-dependent contraction, inositol 1,4,5-trisphosphate (IP₃) formation, and increase in cytosolic free Ca²⁺. Contraction induced by Y₂ and Y₄ agonists was not affected by 0 Ca²⁺, Ca²⁺ channel blockers, or pertussis toxin (PTx), but it was abolished by thapsigargin, U73122 [1-(6-(17-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-25-dione], or the myosin light chain kinase inhibitor ML-9 [1-(5-chloronaphthalene-1-sulfonyl)homopiperazine, HCl]. Y₂-mediated contraction was inhibited by the selective Y₂ antagonist BIIE 0246. Insensitivity to PTx implied that the coupling to G_i did not initiate (Y₁) or contribute (Y₂ and Y₄) to contraction. All Y receptor agonists inhibited cAMP formation in a PTx-sensitive manner. The patterns of contraction and inhibition of cAMP by various Y receptors were corroborated by selective receptor protection. The study demonstrates coexpression of Y₁, Y₂, and Y₄ receptors on smooth muscle negatively coupled to adenylyl cyclase via G_i2. Coupling of Y₂ and Y₄ receptors to G_q determines their ability to induce IP₃-dependent Ca²⁺ release and initiate contraction.

Address correspondence to: Dr. John R. Grider, P.O. Box 908711, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VI 23298. E-mail: jgrider{at}hsc.vcu.edu

This article has been cited by other articles:

				W. Hu, S. Mahavadi, F. Li, and K. S. Murthy Upregulation of RGS4 and downregulation of CPI-17 mediate inhibition of colonic muscle contraction by interleukin-1 Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1991 - C2000. [Abstract] [Full Text] [PDF]

				W. Hu, S. Mahavadi, J. Huang, F. Li, and K. S. Murthy Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G605 - G610. [Abstract] [Full Text] [PDF]